Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
TransMolecular, Inc.
TransMolecular Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma
June 17th, 2008
TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, announced positive interim Phase 1 data for its intravenous formulation of (131)I-TM601 in metastatic melanoma in a published abstract at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). The Phase 1 study demonstrated that intravenously administered radiolabeled TM601 is able to cross the blood-brain barrier, specifically bind to tumor tissue, and is actively internalized by tumor cells, including metastases to the central nervous system. The data were highlighted in ASCO abstract number 20003. This report extends positive data presented by the Company in recurrent glioma in...
Source: Cancer Weekly (2008-06-17)
|
